Oyster Point Pharma (Oyster Point Pharma) 6-1 Month Momentum % : 145.58% (As of May. 08, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-08), Oyster Point Pharma's 6-1 Month Momentum % is 145.58%.

The industry rank for Oyster Point Pharma's 6-1 Month Momentum % or its related term are showing as below:

OYST's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -0.63 vs OYST: 145.58

Competitive Comparison of Oyster Point Pharma's 6-1 Month Momentum %

For the Biotechnology subindustry, Oyster Point Pharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oyster Point Pharma's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Oyster Point Pharma's 6-1 Month Momentum % falls into.

Oyster Point Pharma (NAS:OYST) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oyster Point Pharma (NAS:OYST) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Oyster Point Pharma 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oyster Point Pharma (Oyster Point Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540

Website

https://www.oysterpointrx.com

Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

Executives

Ozawa Clare	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel	director	4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades	director	C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh	director	MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko	officer: Chief Commercial Officer	C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c.	director, 10 percent owner	126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc	10 percent owner	40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau	director, officer: President and CEO	202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner	officer: Chief Financial Officer	202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p.	10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p.	director, 10 percent owner	126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022